Early gastric cancer curative resection after ESD (eCura)
Determines endoscopic curability (eCuraA / C-1 / C-2) from post-ESD/EMR pathology. Fig. 2 table from the JGES gastric ESD/EMR guideline (2nd ed.); logic follows JGCA treatment guideline (7th ed., Mar 2025).
Fig. 2 Evaluation of curability according to tumor-related factors
JGES gastric ESD/EMR guideline 2nd ed. (2020)
pT1a (M), intramucosal; pT1b1 (SM1), SM invasion <500 µm; pT1b2 (SM2), ≥500 µm. UL0/UL1, ulcer/scar. Long diameter on reconstruction. Logic follows JGCA treatment guideline 7th ed. (Mar 2025): differentiated SM1 ≤3 cm is eCuraA.
Complete all items to highlight the matching cell
| Depth | Ulcer | Differentiated | Undifferentiated |
|---|
| ≤3 cm | >3 cm | ≤2 cm | >2 cm |
|---|
| pT1a (M) | UL0 | eCuraA (i) | eCuraA (ii) | eCuraC-2 |
| UL1 | eCuraA (iii) | eCuraC-2 | eCuraC-2 | eCuraC-2 |
| pT1b1 (SM1) | — | eCuraA (iv) | eCuraC-2 | eCuraC-2 | eCuraC-2 |
| pT1b2 (SM2) | — | eCuraC-2 | eCuraC-2 | eCuraC-2 | eCuraC-2 |
* eCuraA requires en bloc resection and HM0, VM0, Ly0, V0
* eCuraB per the 7th-edition expanded-indication definition is not shown in this table; see the guideline text when applicable.
eCuraC-1: meets eCuraA criteria but piecemeal resection or HM1
eCuraC-2: all others (VM1, Ly/V1, SM2+, size out of range, etc.)
Fig. 6 exception: differentiated-dominant with undifferentiated mapping sum >2 cm → eCuraC-2
Fig. 6 exception: undifferentiated component in SM-invasive part → eCuraC-2